CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.91
4.95%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.82
Open* 1.76
1-Year Change* -61.23%
Day's Range* 1.76 - 1.96
52 wk Range 1.62-7.57
Average Volume (10 days) 196.00K
Average Volume (3 months) 2.30M
Market Cap 119.34M
P/E Ratio -100.00K
Shares Outstanding 67.81M
Revenue N/A
EPS -1.89
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 1.91 0.15 8.52% 1.76 1.97 1.76
Nov 30, 2023 1.82 0.06 3.41% 1.76 1.84 1.71
Nov 29, 2023 1.78 -0.02 -1.11% 1.80 1.86 1.73
Nov 28, 2023 1.79 -0.02 -1.10% 1.81 1.88 1.78
Nov 27, 2023 1.86 0.06 3.33% 1.80 1.87 1.79
Nov 24, 2023 1.79 0.03 1.70% 1.76 1.84 1.76
Nov 22, 2023 1.74 -0.04 -2.25% 1.78 1.78 1.66
Nov 21, 2023 1.75 0.08 4.79% 1.67 1.79 1.60
Nov 20, 2023 1.66 -0.09 -5.14% 1.75 1.75 1.61
Nov 17, 2023 1.73 -0.02 -1.14% 1.75 1.77 1.70
Nov 16, 2023 1.73 -0.04 -2.26% 1.77 1.79 1.65
Nov 15, 2023 1.76 -0.14 -7.37% 1.90 1.95 1.75
Nov 14, 2023 1.89 0.09 5.00% 1.80 1.91 1.78
Nov 13, 2023 1.77 0.04 2.31% 1.73 1.78 1.68
Nov 10, 2023 1.73 -0.18 -9.42% 1.91 1.98 1.73
Nov 9, 2023 1.83 0.04 2.23% 1.79 1.88 1.68
Nov 8, 2023 1.83 -0.08 -4.19% 1.91 1.94 1.81
Nov 7, 2023 1.96 0.11 5.95% 1.85 1.98 1.77
Nov 6, 2023 1.81 -0.09 -4.74% 1.90 1.99 1.75
Nov 3, 2023 1.86 0.07 3.91% 1.79 1.88 1.62

Vor Biopharma Inc. Events

Time (UTC) Country Event
Tuesday, December 5, 2023

Time (UTC)

18:30

Country

US

Event

Vor Biopharma Inc at JMP Securities Hematology and Oncology Summit (Virtual)
Vor Biopharma Inc at JMP Securities Hematology and Oncology Summit (Virtual)

Forecast

-

Previous

-
Thursday, March 21, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Vor Biopharma Inc Earnings Release
Q4 2023 Vor Biopharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 93.418 69.018 43.366 10.417 2.86
Selling/General/Admin. Expenses, Total 28.868 21.489 11.748 4.217 0.427
Research & Development 64.55 47.529 31.618 6.2 2.433
Operating Income -93.418 -69.018 -43.366 -10.417 -2.86
Interest Income (Expense), Net Non-Operating 1.324 0.119 0.029 -0.422 -1.292
Net Income Before Taxes -92.094 -68.899 -43.337 -10.839 -4.152
Net Income After Taxes -92.094 -68.899 -43.337 -10.839 -4.152
Net Income Before Extra. Items -92.094 -68.899 -43.337 -10.839 -4.152
Net Income -92.094 -68.899 -43.337 -10.839 -4.152
Total Adjustments to Net Income 0 -1.228 -5.925 -1.773 0
Income Available to Common Excl. Extra. Items -92.094 -70.127 -49.262 -12.612 -4.152
Income Available to Common Incl. Extra. Items -92.094 -70.127 -49.262 -12.612 -4.152
Diluted Net Income -92.094 -70.127 -49.262 -12.612 -4.152
Diluted Weighted Average Shares 39.5514 33.4332 35.6459 35.6459 35.6459
Diluted EPS Excluding Extraordinary Items -2.32846 -2.09752 -1.38198 -0.35381 -0.11648
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -2.32846 -2.09752 -1.38198 -0.35381 -0.11648
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 32.174 30.422 24.725 24.101 21.792
Selling/General/Admin. Expenses, Total 8.277 8.507 7.663 7.226 6.459
Research & Development 23.897 21.915 17.062 16.875 15.333
Operating Income -32.174 -30.422 -24.725 -24.101 -21.792
Interest Income (Expense), Net Non-Operating 2.195 1.989 0.815 0.313 0.133
Net Income Before Taxes -29.979 -28.433 -23.91 -23.788 -21.659
Net Income After Taxes -29.979 -28.433 -23.91 -23.788 -21.659
Net Income Before Extra. Items -29.979 -28.433 -23.91 -23.788 -21.659
Net Income -29.979 -28.433 -23.91 -23.788 -21.659
Total Adjustments to Net Income 0 0 0
Income Available to Common Excl. Extra. Items -29.979 -28.433 -23.91 -23.788 -21.659
Income Available to Common Incl. Extra. Items -29.979 -28.433 -23.91 -23.788 -21.659
Diluted Net Income -29.979 -28.433 -23.91 -23.788 -21.659
Diluted Weighted Average Shares 67.0331 66.2657 45.4583 38.009 37.4371
Diluted EPS Excluding Extraordinary Items -0.44723 -0.42908 -0.52598 -0.62585 -0.57854
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.44723 -0.42908 -0.52598 -0.62585 -0.57854
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 236.95 214.399 49.106 7.539 0.936
Cash and Short Term Investments 230.245 207.469 48.539 6.466 0.929
Cash & Equivalents 57.706 119.801 48.539 6.466 0.929
Prepaid Expenses 4.368 4.836 0.467 0.868 0.007
Other Current Assets, Total 2.337 2.094 0.1 0.205 0
Total Assets 299.366 242.59 75.908 9.826 1.007
Property/Plant/Equipment, Total - Net 57.078 22.523 21.845 0.728 0.071
Property/Plant/Equipment, Total - Gross 61.688 24.607 22.571 0.849 0.101
Accumulated Depreciation, Total -4.61 -2.084 -0.726 -0.121 -0.03
Other Long Term Assets, Total 5.338 5.668 4.957 1.559 0
Total Current Liabilities 13.119 10.153 10.207 2.186 7.774
Accounts Payable 1.772 1.545 2.361 0.693 0.038
Accrued Expenses 11.161 8.174 7.123 0.938 0.577
Notes Payable/Short Term Debt 0 0 0 0 4.459
Other Current Liabilities, Total 0.186 0.434 0.723 0.555 2.7
Total Liabilities 48.759 26.327 27.637 2.186 7.774
Total Long Term Debt 0 0 0 0 0
Total Equity 250.607 216.263 48.271 7.64 -6.767
Redeemable Preferred Stock 0 107.336 25.069 0.002
Common Stock 0.007 0.004 0.001 0 0
Additional Paid-In Capital 473.587 346.382 2.158 0.458 0.279
Retained Earnings (Accumulated Deficit) -222.217 -130.123 -61.224 -17.887 -7.048
Total Liabilities & Shareholders’ Equity 299.366 242.59 75.908 9.826 1.007
Total Common Shares Outstanding 65.9961 37.1747 37.1279 35.6459 35.6459
Other Liabilities, Total 35.64 16.174 17.43
Short Term Investments 172.539 87.668
Preferred Stock - Non Redeemable, Net 0
Unrealized Gain (Loss) -0.77
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 164.438 191.393 216.898 236.95 142.729
Cash and Short Term Investments 160.098 186.902 210.2 230.245 136.067
Cash & Equivalents 45.026 32.212 42.455 57.706 60.827
Prepaid Expenses 3.673 3.952 6.239 4.368 4.891
Other Current Assets, Total 0.667 0.539 0.459 2.337 1.771
Total Assets 223.023 250.986 277.533 299.366 206.373
Property/Plant/Equipment, Total - Net 52.086 53.912 55.431 57.078 58.353
Property/Plant/Equipment, Total - Gross 59.284 60.219 60.877 61.688 62.33
Accumulated Depreciation, Total -7.198 -6.307 -5.446 -4.61 -3.977
Other Long Term Assets, Total 6.499 5.681 5.204 5.338 5.291
Total Current Liabilities 15.388 12.717 12.579 13.119 11.102
Accounts Payable 1.309 1.648 3.216 1.772 0.824
Accrued Expenses 14.017 10.947 9.198 11.161 10.045
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.062 0.122 0.165 0.186 0.233
Total Liabilities 48.242 46.536 47.318 48.759 47.639
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 32.854 33.819 34.739 35.64 36.537
Total Equity 174.781 204.45 230.215 250.607 158.734
Redeemable Preferred Stock
Common Stock 0.007 0.007 0.007 0.007 0.004
Additional Paid-In Capital 488.873 485.508 481.032 473.587 358.215
Retained Earnings (Accumulated Deficit) -313.819 -280.629 -250.65 -222.217 -198.307
Total Liabilities & Shareholders’ Equity 223.023 250.986 277.533 299.366 206.373
Total Common Shares Outstanding 67.7855 67.4336 66.9349 65.9961 38.3932
Short Term Investments 115.072 154.69 167.745 172.539 75.24
Preferred Stock - Non Redeemable, Net
Unrealized Gain (Loss) -0.28 -0.436 -0.174 -0.77 -1.178
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -92.094 -68.899 -43.337 -10.839 -4.152
Cash From Operating Activities -85.144 -69.144 -36.292 -9.855 -2.661
Cash From Operating Activities 2.525 1.434 0.605 0.091 0.02
Non-Cash Items 17.118 7.332 2.124 0.748 1.408
Changes in Working Capital -12.693 -9.011 4.316 0.145 0.063
Cash From Investing Activities -94.091 -91.651 -4.161 -0.748 0
Capital Expenditures -8.462 -3.894 -4.161 -0.748 0
Cash From Financing Activities 117.14 232.911 82.526 17.699 2.464
Issuance (Retirement) of Stock, Net 117.14 235.126 82.526 17.699 0
Issuance (Retirement) of Debt, Net 0 2.464
Net Change in Cash -62.095 72.116 42.073 7.096 -0.197
Other Investing Cash Flow Items, Total -85.629 -87.757
Financing Cash Flow Items 0 -2.215
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -28.433 -92.094 -68.184 -44.396 -22.737
Cash From Operating Activities -24.268 -85.144 -66.798 -47.896 -22.904
Cash From Operating Activities 0.837 2.525 1.893 1.001 0.426
Non-Cash Items 4.819 17.118 10.987 6.119 2.731
Changes in Working Capital -1.491 -12.693 -11.494 -10.62 -3.324
Cash From Investing Activities 6.498 -94.091 2.945 -9.757 -7.055
Capital Expenditures -0.094 -8.462 -8.141 -7.843 -2.011
Cash From Financing Activities 2.519 117.14 4.879 0.804 0.2
Financing Cash Flow Items -0.717 0 0 0 0
Issuance (Retirement) of Stock, Net 3.236 117.14 4.879 0.804 0.2
Net Change in Cash -15.251 -62.095 -58.974 -56.849 -29.759
Other Investing Cash Flow Items, Total 6.592 -85.629 11.086 -1.914 -5.044
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
RA Capital Management, LP Hedge Fund 33.6827 22748880 0 2023-08-10 LOW
Fidelity Management & Research Company LLC Investment Advisor 11.2504 7598355 -214681 2023-06-30 LOW
Paradigm BioCapital Advisors LP Investment Advisor 9.5671 6461467 -16532 2023-06-30 MED
5AM Ventures Venture Capital 9.4194 6361723 0 2023-06-30 MED
Laurion Capital Management LP Hedge Fund 4.7127 3182889 0 2023-06-30 HIGH
Invus Public Equities Advisors, LLC Investment Advisor 3.98 2688015 -104790 2023-06-30 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.908 1964007 1509942 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.5356 1712481 133183 2023-06-30 LOW
Woodline Partners LP Hedge Fund 1.6452 1111123 0 2023-06-30 HIGH
Johnson & Johnson Innovation-JJDC, Inc. Venture Capital 1.5912 1074658 0 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.0696 722405 406458 2023-06-30 LOW
Baker Bros. Advisors LP Hedge Fund 0.9385 633848 0 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.9317 629286 578173 2023-06-30 LOW
Sarissa Capital Management, L.P. Hedge Fund 0.915 618000 0 2023-06-30 LOW
Ang (Robert M.D.) Individual Investor 0.585 395070 -12657 2023-09-01 LOW
OUP Management Co., LLC Venture Capital 0.5548 374714 0 2023-06-30 LOW
Ensign Peak Advisors, Inc. Foundation 0.5124 346087 0 2023-06-30 LOW
Thrivent Asset Management, LLC Investment Advisor 0.4629 312652 -2557 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.4485 302878 242434 2023-06-30 LOW
Bellecapital Partners AG Investment Advisor/Hedge Fund 0.1876 126726 0 2023-02-28 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vor Biopharma Inc. Company profile

About Vor Biopharma Inc

Vor Biopharma Inc is a clinical-stage cell therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solution for patients suffering from hematological malignancies. The Company develops engineered hematopoietic stem cell (eHSC) product candidate, VOR33, VCAR33, which together are the treatment paradigm for acute myeloid leukemia (AML) and other hematological malignancies. The Company’s platform provides treatment for both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates (ADCs), bispecific antibodies and CAR-T cell treatments, including CD33 CAR-T. The Company uses genome engineering technology to remove CD33 surface targets from hematopoietic stem cells (HSCs) to create VOR33. The Company’s eHSCs, such as VOR33, are designed to be used with therapeutics such as VCAR33, that would provide tumor-specific killing.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Vor Biopharma Inc revenues was not reported. Net loss applicable to common stockholders increased 65% to $51.9M. Higher net loss reflects Research and development - Balancing val increase of 67% to $33.2M (expense), General and administrative - Balancing increase from $7M to $14.4M (expense), Stock-based Compensation in R&D increase from $374K to $1.6M (expense).

Industry: Biotechnology & Medical Research (NEC)

100 Cambridgepark Drive
Suite 101
CAMBRIDGE
MASSACHUSETTS 02140
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.63 Price
-0.100% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading